edaravone has been researched along with Parkinsonian Disorders in 3 studies
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Parkinson's model was developed by chronic administration of a pesticide rotenone that inhibits mitochondrial complex I resulting in generation of reactive oxygen species." | 1.51 | Edaravone-caffeine combination for the effective management of rotenone induced Parkinson's disease in rats: An evidence based affirmative from a comparative analysis of behavior and biomarker expression. ( Bandookwala, M; Khairnar, A; Sahu, AK; Sengupta, P; Sharma, M; Thakkar, D, 2019) |
| "Edaravone is a powerful free radical scavenger used in clinical treatment for cerebral ischemic stroke." | 1.39 | Edaravone prevents neurotoxicity of mutant L166P DJ-1 in Parkinson's disease. ( Li, B; Xu, Z; Yu, D, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bandookwala, M | 1 |
| Sahu, AK | 1 |
| Thakkar, D | 1 |
| Sharma, M | 1 |
| Khairnar, A | 1 |
| Sengupta, P | 1 |
| Li, B | 1 |
| Yu, D | 1 |
| Xu, Z | 1 |
| Xiong, N | 1 |
| Xiong, J | 1 |
| Khare, G | 1 |
| Chen, C | 1 |
| Huang, J | 1 |
| Zhao, Y | 1 |
| Zhang, Z | 1 |
| Qiao, X | 1 |
| Feng, Y | 1 |
| Reesaul, H | 1 |
| Zhang, Y | 1 |
| Sun, S | 1 |
| Lin, Z | 1 |
| Wang, T | 1 |
3 other studies available for edaravone and Parkinsonian Disorders
| Article | Year |
|---|---|
Edaravone-caffeine combination for the effective management of rotenone induced Parkinson's disease in rats: An evidence based affirmative from a comparative analysis of behavior and biomarker expression.
Topics: Animals; Antioxidants; Behavior, Animal; Biomarkers; Brain; Caffeine; Drug Synergism; Edaravone; Lip | 2019 |
Edaravone prevents neurotoxicity of mutant L166P DJ-1 in Parkinson's disease.
Topics: Animals; Antipyrine; Apoptosis; Cell Line, Tumor; Edaravone; Free Radical Scavengers; Mice; Mitochon | 2013 |
Edaravone guards dopamine neurons in a rotenone model for Parkinson's disease.
Topics: Animals; Antipyrine; bcl-2-Associated X Protein; Behavior, Animal; Dopamine; Edaravone; Free Radical | 2011 |